Algernon Pharmaceuticals has announced that its Phase 2 trial of oral NP-120 (ifenprodil) in treating chronic cough associated with…
Vanda Pinto, PhD
Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanda Pinto, PhD
Small extracellular vesicles (EVs) released from umbilical cord stem cells seem to carry molecules that can inhibit the TGF-beta signaling…
Idiopathic pulmonary fibrosis (IPF) is associated with poorer prognosis in patients with lung cancer, a study shows. People with…
A variant of the MUC5B gene, known as the rs35705950 (T) allele, appears to lead to better survival in people…
VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung…
A modified protein called citrullinated vimentin (cit-vim), released by immune cells in response to harmful pollutants, may contribute to lung…
Exposure to certain work- and environment-related elements may be the cause of some idiopathic pulmonary fibrosis (IPF) cases, a…